Heparin IV Bags Recalled Due to Sterility Assurance Failure
Central Admixture Pharmacy Services is recalling heparin IV bags due to lack of sterility assurance and missing validation data for decontamination cycles. The recall affects 358 bags distributed nationwide.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall of a high-risk injectable medication with lack of sterility assurance due to missing sterilization validation data. No illnesses or hospitalizations have been reported; the contamination risk is theoretical based on inadequate validation.
Plain-English summary
Central Admixture Pharmacy Services, Inc. is recalling heparin 2500 units in 0.9% sodium chloride 250mL IV bags because validation data for decontamination cycles is lacking. Without this data, the manufacturer cannot assure the sterility of these products.
The recalled lots are 36-249694 and 36-249695, both expiring July 31, 2023. A total of 358 bags were distributed nationwide to healthcare facilities and pharmacies.
Sterile injectable medications must be free from bacterial contamination to prevent patient harm. The absence of validation data means these specific IV bags may not have undergone adequate sterilization. Patients and healthcare providers who have received these products should contact the manufacturer or their healthcare provider if they have concerns.
The recalled product
- Product
- heparin 2500 units added to 0.9% sodium chloride 250mL, CONCENTRATION = 10 units/mL, IV Bag, Rx only, Cental Admixture Pharmacy Services, Inc., 2200 South 43rd Avenue, Pheonix, AZ 85043, NDC: 72196-8000-1
- Manufacturer
- Central Admixture Pharmacy Services, Inc.
- Category
- Drug — Injectable / IV
- Hazard
- sterility-failure
- contamination-risk
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (3)
- Lot: 36-249694
- 36-249695
- Exp. 7/31/2023.
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27